Shares of Intersect ENT (NASDAQ:XENT) remained unaffected after the company reported Q2 results.
Quarterly Results
Earnings per share increased 24.62% year over year to ($0.49), which missed the estimate of ($0.43).
Revenue of $27,349,000 up by 179.64% year over year, which missed the estimate of $28,020,000.
Guidance
Intersect ENT hasn’t issued any earnings guidance for the time being.
Revenue guidance hasn’t been issued by the company for now.
Conference Call Details
Date: Aug 06, 2021
Time: 08:30 AM
ET Webcast URL: https://services.choruscall.com/mediaframe/webcast.html?webcastid=42bLgRiD
Recent Stock Performance
Company’s 52-week high was at $26.98
52-week low: $14.68
Price action over last quarter: Up 32.04%
Company Description
Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer’s PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.
